Tuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes?

Hdl Handle:
http://hdl.handle.net/10144/619156
Title:
Tuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes?
Authors:
van Griensven, J; Mohammed, R; Ritmeijer, K; Burza, S; Diro, E
Journal:
Open Forum Infectious Diseases
Abstract:
Visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection remains a major problem in Ethiopia, India, and Brazil. Tuberculosis (TB), a treatable factor, could contribute to high mortality (up to 25%) in VL-HIV coinfection. However, the current evidence on the prevalence and clinical impact of TB in VL-HIV coinfection is very limited. In previous reports on routine care, TB prevalence ranged from 5.7% to 29.7%, but information on how and when TB was diagnosed was lacking.
Publisher:
Oxford University Press
Issue Date:
Apr-2018
URI:
http://hdl.handle.net/10144/619156
DOI:
10.1093/ofid/ofy059
PubMed ID:
29732379
Submitted date:
2018-05-18
Language:
en
ISSN:
2328-8957
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorvan Griensven, Jen
dc.contributor.authorMohammed, Ren
dc.contributor.authorRitmeijer, Ken
dc.contributor.authorBurza, Sen
dc.contributor.authorDiro, Een
dc.date.accessioned2018-05-22T14:49:27Z-
dc.date.available2018-05-22T14:49:27Z-
dc.date.issued2018-04-
dc.date.submitted2018-05-18-
dc.identifier.citationTuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes? 2018, 5 (4):ofy059 Open Forum Infect Disen
dc.identifier.issn2328-8957-
dc.identifier.pmid29732379-
dc.identifier.doi10.1093/ofid/ofy059-
dc.identifier.urihttp://hdl.handle.net/10144/619156-
dc.description.abstractVisceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection remains a major problem in Ethiopia, India, and Brazil. Tuberculosis (TB), a treatable factor, could contribute to high mortality (up to 25%) in VL-HIV coinfection. However, the current evidence on the prevalence and clinical impact of TB in VL-HIV coinfection is very limited. In previous reports on routine care, TB prevalence ranged from 5.7% to 29.7%, but information on how and when TB was diagnosed was lacking.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsArchived with thanks to Open Forum Infectious Diseasesen
dc.titleTuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes?en
dc.identifier.journalOpen Forum Infectious Diseasesen
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.